Schizophrenia

A new literature review shows that globally, a majority of both men and women with schizophrenia experience some form of sexual dysfunction.

The LYNX drug development platform is able to deliver drug consistently, while minimizing peaks and troughs of drug levels compared to daily medicine.

The extended-release injectable suspension treatment represents the first subcutaneous, long-acting formulation of risperidone.

The long-acting injectable can be administered once every 2 months to either treat schizophrenia or serve as a maintenance monotherapy for bipolar disorder.

New research highlights the shared and unique characteristics of sleep and rest-activity rhythm measures among patients with schizophrenia.

The risk of minor nuisances, violating APS law, and violating criminal law were higher in the nonadherence group.

Various psychiatric symptoms, including more severe negative symptoms, lower cognition status, and lower excited symptoms were significantly linked to drug-induced parkinsonism induction.

Children definite motor problems were more likely to have psychotic experiences compared to children with no definite motor problems.

A new cross-sectional analysis suggest there are few options available for patients with schizophrenia or a serious mood disorder.

Anhedonia had the highest expected influence in the most comprehensive network analysis, showing connections with negative and positive symptoms and functional domains.

Patients treated with LAIAs had a lower risk of hospitalization for any cause, hospitalizations for psychiatric disorders, hospitalizations for schizophrenia, and incident suicide attempts compared to patients treated with oral antipsychotics.

A 6-year mirror analysis of risperidone, once-monthly paliperidone palmitate or once-monthly aripiprazole concludes suggesting the regimens may serve as an alternative to clozapine.

The treatment represents the only FDA approved orally dissolving sublingual film for this patient population.

Clinical decision support intervention resulted in a rate of change in total modifiable CV risk that was 4% lower among intervention patients compared to control.

Melatonin is seen as the most promising treatment in this patient population.

The treatment met the pre-specified primary endpoint of significantly less weight gain in the ENLIGHTEN-Early trial.

There was an elevated risk of violence perpetration in both men and women with schizophrenia spectrum disorder.

Ineligible patients with schizophrenia have a higher risk of hospitalization for a number of reasons, including suicide attempts.

Brexipiprazole has been previously approved for adults with schizophrenia and adults with major depressive disorder.

Between 20-30% of patients with schizophrenia do not respond to the first-line antipsychotic treatment.

Six-month paliperidone palmitate is the only twice-yearly injectable treatment for patients with schizophrenia.

There was little difference in hospitalization and mortality rates between vaccinated schizophrenia patients and vaccinated control patients.

Schizophrenia PRS was linked to increased disorganized symptom dimension scores.

Severe mental disorders had the highest odds ratios for the risk of mortality.

The oral combination therapy can also be used as acute treatment for manic or mixed episodes.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

In a poster presented at APA, researchers review current clinical practice guidelines for schizophrenia.

Henry Nasrallah, MD, discusses patient factors that lead to long-acting injectable treatment in patients with schizophrenia.